Add Row
Add Element
cropper
update
National Cannabis Newswire
update
Add Element
  • Home
  • Categories
    • news
    • trends
    • insights
    • industry
    • legalization
    • health
    • culture
    • advocacy
    • Brands
    • New Mexico Dispensaries
    • Arizona Dispensaries
December 14.2025
3 Minutes Read

What the Potential Rescheduling of Cannabis Could Mean for the Industry

Cannabis & Tech Today logo in blue and green.

The Potential Shift: From Schedule I to Schedule III

In a surprising development, the Trump administration is contemplating a significant shift in cannabis classification. As reported by The Washington Post, this potential executive order would change marijuana's status from the highly restrictive Schedule I to Schedule III of the Controlled Substances Act. This move could happen as soon as December 15, 2025, providing a breath of fresh air for the cannabis industry and its advocates.

Understanding the Implications of Rescheduling Cannabis

This change could open doors for marijuana-related research and access, similar to how ketamine is treated. Currently labeled as Schedule I, cannabis is viewed as having no accepted medical use, alongside substances like heroin. In contrast, Schedule III substances, which include certain steroids and codeine products, are recognized for their medical benefits.

According to cannabis industry analyst Brian Vicente, this adjustment could profoundly impact business operations: “This monumental change will have a massive, positive effect on thousands of state-legal cannabis businesses.” The current taxation structure under Internal Revenue Code Section 280E limits these companies’ ability to take deductions, leading to exorbitant effective tax rates. Rescheduling could alleviate some of this financial strain, empowering these businesses to thrive.

Industry Reactions: Hopes and Concerns

The cannabis industry's sentiment reflects a mixture of excitement and cautious optimism. Jim Belushi, founder of Belushi’s Farm, passionately declared, “ABOUT TIME!!!” Others, including Mark Lewis from Lüt banks, believe this might represent one of the most significant drug policy shifts in decades, allowing for enhanced scientific research and patient access to cannabis products. However, the looming challenges of current legislative bottlenecks, such as the lack of advancement on the SAFE Banking Act, temper this enthusiasm.

Furthermore, the inconsistency surrounding the administration’s communications regarding hemp product restrictions raises questions. Tamara Anderson from Culinary & Cannabis pointedly asked why this rescheduling is a priority now and stressed the need for responsible measures. This inconsistency exemplifies the complexities of cannabis policy, where progress in one area may clash with setbacks in another.

Future Predictions: What Lies Ahead for the Cannabis Industry?

If the order does go forward, industries reliant on cannabis may see a transformation resembling typical pharmaceutical pathways where doctors prescribe authorized products. Spherex’s Ryan Hunter highlighted that this change could make cannabis more accessible in non-medical states while prioritizing therapeutic products, broadening public acceptance and usage.

As these strategic discussions unfold in the Oval Office, consumer perspectives may also change, particularly regarding medical use. Polls indicate a steady increase in support for medical cannabis, indicating the public's shifting attitude toward marijuana policies. Should this order pass, we may witness an invigorated public discourse on cannabis usage, research, and its societal implications.

As the industry watches closely, one thing becomes clear: the potential rescheduling of cannabis could signal a new era in the cannabis sector, reinforcing the need for continued advocacy and informed legislation. In a rapidly changing landscape influenced by technology and societal needs, those entrenched in the cannabis industry must remain diligent and prepared for what lies ahead.

trends

3 Views

0 Comments

Write A Comment

*
*
Related Posts All Posts

What Medicare’s CBD Coverage Means for Senior Wellness and Industry Tech

Update Shifting Perspectives on CBD for Senior Wellness In recent developments, the prospect of Medicare covering hemp-derived products has ignited discussions about the future of CBD, especially for seniors who rely on these wellness aids. A report from Cannatech Today emphasizes that this move could redefine how older adults access care while revealing the contradictions in current federal regulations. The Historic Move from Medicare The Centers for Medicare & Medicaid Services (CMS) has proposed to cover certain legal CBD products under Medicare Advantage programs, a pivotal shift that recognizes the medicinal potential of non-intoxicating cannabinoids. This initiative could bring relief to the millions of older Americans who have relied on CBD to manage pain, anxiety, and other conditions. Advocates, including organizations like Realm of Caring, hail this change as a much-needed validation that cannabinoids can significantly enhance the quality of life for seniors. Sasha Kalcheff-Korn, the organization’s executive director, mentions that government recognition pushes the body of research for CBD into the forefront of health conversations, making it a legitimate topic within public health discussions. Challenges with Federal Restrictions While the Medicare advancement is promising, a sharp contradiction looms as Congress considers defining hemp more restrictively. The implications of this change are staggering; many current CBD products may become illegal, disrupting access for consumers who rely on them. Price-hikes, product reformulations, and discontinuations await customers if the definition change goes through. This scenario poses immediate risks for seniors who depend on CBD products to manage chronic pain and improve overall wellness. With nearly one-third of Americans aged 50 and over currently utilizing CBD, the potential loss of these products threatens not just individual health but could reverberate through the entire wellness marketplace. Potential Path to Legalization Interestingly, the clash between Medicare's acceptance of CBD and impending federal restrictions may catalyze a push for comprehensive cannabis reform. With a potent political spotlight now on seniors needing accessible CBD products, there might be a greater call for clarity and consistency in legislation. As highlighted in a Forbes article, the conflict introduces an opportunity for advocates to compel lawmakers to recognize the health benefits of cannabinoids beyond the stigma of recreational uses. The duality of these federal messages could ultimately reform how Congress perceives and legislates cannabis. As awareness continues to grow alongside pressure from constituents feeling the consequences firsthand, the industry might finally witness meaningful advancements in legalization efforts. What's Next for the CBD Market? The reality is, without proactive measures, millions of older adults could soon find themselves without access to the products they trust. The current state of uncertainty, however, may also serve as a rallying point for businesses, consumers, and advocates alike. If pushed towards advocacy and engagement, the drive for national cannabis reform could reshape existing conversations around the cannabis industry. Ultimately, as seniors voice their needs, the narrative may shift from prohibition to understanding, potentially leading to a framework that addresses not just CBD, but a wider spectrum of hemp-derived products. Call to Action For those invested in the future of CBD and senior wellness, now is the time to engage. Stay informed about legislative developments, advocate for the rights of seniors to access cannabis products, and consider joining organizations dedicated to education and positive policy changes in this rapidly evolving landscape.

Revolutionizing Epilepsy Treatments: Engineering CBD-like Solutions Without Cannabis

Update Molecular Innovation in Epilepsy Treatment In a groundbreaking study led by researchers at the University of Nevada, Las Vegas (UNLV), the promise of treating pediatric epilepsy is being realized without cannabis-derived products. The research focuses on engineering cannabidiol-like seizure treatments using components derived from the commonplace caraway seed, which may provide a profound advancement in neuropharmacology. The Science Behind the Synthesis By extracting (+)-carvone from caraway's essential oils, the team has successfully synthesized various cannabidiol analogs. This meticulous five-step synthesis process has yielded compounds like (+)-CBD-hex and (+)-CBD-oct, designed to enhance seizure suppression while minimizing psychoactive side effects typically associated with tetrahydrocannabinol (THC). Initial preclinical trials in murine models revealed that these synthetic analogs, particularly (+)-CBD-oct, increased neural stability without causing the sedation seen in existing treatments, such as benzodiazepines. The Impact on Pediatric Patients Dustin Hines, a professor at UNLV, emphasized the critical need for alternatives, stating, "Childhood seizure disorders are often resistant to available drugs. These fully synthetic compounds not only prevent seizures and reduce related deaths but also promote healthier brain cell development." Such progress is vital, as traditional remedies can obstruct cognitive development, severely impacting a child's quality of life. Path to Neurodevelopmental Restoration Beyond their anticonvulsant properties, these caraway-derived compounds are being studied for their potential to normalize neuronal architecture. The results in animal models of epilepsy have been promising, indicating a capacity to rectify abnormal neuronal maturation without the cognitive impairments that benzodiazepines typically cause. "It is encouraging to help build the foundation for future treatment options that could one day offer families safer and more effective choices," noted Adriana Carrillo, a senior at UNLV and co-researcher in the study. Addressing the Treatment Gap in Epilepsy Approximately one-third of epilepsy patients remain treatment-resistant despite various antiseizure medications. The development of synthetic cannabidiol mimics not only fills this gap but also holds the potential to dictate safer therapeutic approaches. As research progresses, understanding the pharmacodynamics and long-term effects of these new compounds will be paramount. Looking Ahead: The Future of Cannabinoid Therapy As the field of neuropharmacology advances, the introduction of synthetic CBD analogs signifies a revolution in epilepsy treatment. With potential implications for broader applications beyond epilepsy, continued research and clinical trials will be necessary to ascertain their efficacy and safety profiles, and to explore the landscape of potential drug interactions. For industry technologists and stakeholders in the medical field, this innovation invites a closer examination of the intersection between traditional botanical extracts and modern pharmaceutical approaches. By supporting further research, we can facilitate the development of treatments that offer hope to families struggling with pediatric epilepsy. Call to Action: Support the Research for Better Treatments Engagement in these advancements is crucial. By advocating for research funding and supporting relevant initiatives within the medical community, stakeholders can play a role in advancing effective therapies for epilepsy and beyond.

Trump's Executive Order: Cannabis Reclassified to Schedule III - What It Means for the Industry

Update Trump's Groundbreaking Move for Cannabis: A Shift in Federal Policy In a transformative executive order signed on December 18, 2025, President Donald Trump directed federal agencies to reclassify marijuana from Schedule I to Schedule III under the Controlled Substances Act. This historic shift acknowledges the established medical benefits of cannabis while adjusting its legal perception amid a changing societal landscape. Understanding the Change: What Does Schedule III Mean? Currently, substances classified as Schedule I, such as heroin and LSD, are considered to have no accepted medical use and carry the highest abuse potential. In contrast, Schedule III includes medications like certain steroids and ketamine, both recognized for their medical application with moderate to low risks of abuse. For industry stakeholders and consumers alike, this reclassification signals a significant reduction in the legal stigma surrounding cannabis, allowing for broader acceptance and recognition of its therapeutic potential. Easing Restrictions: A Boom for the Cannabis Industry The immediate impact of this policy includes the potential elimination of IRS Section 280E, a longstanding hurdle barring cannabis companies from deducting ordinary business expenses. Tax rates could drop from exorbitant levels of 70-90 percent to around 20 percent, akin to other industries. This financial relief could empower cannabis businesses, promoting hiring, innovation, and capital influx, echoing sentiments from leaders like Brian Vicente of Vicente LLP, who highlights the monumental positive effect this will have on state-legal cannabis enterprises. The Broader Implications of Cannabis Reclassification While this reclassification does not legalize recreational use federally, it opens the door for enhanced medical research by streamlining the approval process for studies related to cannabis's medical applications. The White House emphasizes an increased focus on research to inform patients and healthcare providers, bridging gaps in medical guidelines that currently exist due to restrictive regulations. Industry Reactions: Acknowledgment and Anticipation Industry leaders view this executive order as a vital step forward. Ben Kovler, CEO of Green Thumb Industries, expressed that the move validates the therapeutic uses of cannabis known by millions. Cristy Aranguiz, a CEO in the sector, shared that this change significantly benefits patients relying on cannabis for pain relief and improved quality of life, emphasizing the intersection of advocacy and real-world impact. Challenges Ahead: Understanding the Limits of Rescheduling Despite the progress heralded by this decision, federal possession of cannabis without a prescription remains illegal, highlighting that rescheduling alone does not fully eliminate the discrepancies between state and federal policies. As cautionary notes echo across the industry, there remains a call for Congress to take further steps towards comprehensive legalization. Conclusion: The Future of Cannabis Industry Dynamics This landmark decision could catalyze significant changes within the cannabis industry, a sector poised for rapid growth and evolving regulatory landscapes. With a heightened focus on delving into the scientific understanding of cannabis, continued advocacy, and legislative efforts tailored towards full legalization appear more promising than ever. Now is the time for industry professionals to navigate this shifting terrain carefully, balancing innovation with compliance in a world where cannabis is increasingly recognized for its valuable contributions to health and wellness.

Terms of Service

Privacy Policy

Core Modal Title

Sorry, no results found

You Might Find These Articles Interesting

T
Please Check Your Email
We Will Be Following Up Shortly
*
*
*